Registro:

Referencias:

• Fareed, J., Hoppensteadt, D., Bick, R., An update on heparins at the beginning of the new millennium (2000) Semin. Thromb. Haemost., 26 (1), pp. 5-21
• Doutremepuich, C., Azougagh Oualane, F., Doutremepuich, F., Fareed, J., New class of heparin derivates with a potent antithrombotic effect and a very limited hemorrhagic activity (1996) Thromb. Res., 83 (3), pp. 217-228
• Brigimshaw, G.F., Shamberge, J.N., Identification of two distinct heparin cofactors in human plasma. Separation and purification (1974) Arch. Biochem. Biophys., 161, pp. 683-690
• Tollefsen, D., Majerus, D.W., Blank, M.K., Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma (1982) J. Biol. Chem., 257, pp. 2162-2169
• Tollefsen, D., Insight into the mechanism of action of heparin cofactor II (1995) Thromb. Haemost., 74 (5), pp. 1209-1214
• Bedayan, P., Boccalon, H., Dupouy, D., Boneu, B., Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins (1994) Thromb. Haemost., 71 (5), pp. 576-580
• Cofrancesco, E., Boschetti, C., Leonardi, F.G., Cortellaro, M., Dematan sulphate for the treatment of disseminated intravascular coagulation (DIC) in acute leukaemia: A randomised, heparin-controlled pilot study (1994) Thromb. Res., 7, pp. 65-75
• Di Carlo, V., Agnelli, G., Prandoni, P., Coccheri, S., Gensini, G.F., Gianese, F., Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer (1999) Thromb. Haemost., 82, pp. 30-34
• Fernández De Recondo, M.E., Legorburu, C., Monge, J.C., Recondo, E.F., Heparin and Concanavalin a interaction: Isolation of a fraction with higher anticoagulant activity (1988) Biochem. Biophys. Res. Commun., 155 (1), pp. 216-223
• Monge, J.C., Recondo, E.F., Fernández De Recondo, M.E., Heparin and Concanavalin a interaction as a model for studying the mechanism of the anticoagulant activity (1989) Thromb. Res., 54, pp. 237-243
• Monge, J.C., Legorburu, C., Fernandez De Recondo, M.E., Recondo, E., Heparin and Concanavalin interaction: A useful model for study the mechanism of anticoagulant activity (1989) Ann. N.Y. Acad. Sci., 556, pp. 462-464
• Fernandez De Recondo, M.E., Monge, J.C., Recondo, E.F., Interaction of concanavalin a with a fraction of dermatan sulfate containing a very high anticoagulant activity (1995) Cell. Mol. Biol., 41 (4), pp. 465-472
• Calabrese, G.C., Recondo, M.M., Fernández De Recondo, M.E., Recondo, E.F., The first component of the human complement system recognizes the active fraction of heparin (1997) Cell. Mol. Biol., 43 (2), pp. 237-242
• Calabrese, G.C., Leocata Nieto, F., Recondo, E.F., Fernandez De Recondo, M.E., An active fraction of unfractionated heparin from a natural source is recognized by the first component of the complement system (2001) Cell. Mol. Biol., 47 (17), pp. 127-131
• Calabrese, G.C., Recondo, E.F., Fernández De Recondo, M.E., Antithrombin and first complement protein recognize the same active heparin fraction (2002) Thromb. Res., 105, pp. 537-541
• Bing, D., Purification of the first component of human complement by affinity chromatography on human gamma globulin linked to sepharose (1971) J. Immunol., 107 (5), pp. 1243-1249
• Bing, D., Nature of active site of a subunit of the first component of human complement (1969) Biochemistry, 8 (11), pp. 4503-4509
• Sie, P., Dupouy, D., Pichon, J., Boneu, B., Constitutional heparin co-factor II deficiency associated with recurrent thrombosis (1985) Lancet, 24, pp. 414-416
• Twlikki, T., Terho, T., Hartiala, K., Method for determination of the sulfate content of glycosaminoglycans (1971) Anal. Biochem., 41, pp. 471-476
• Pavao, M., Aiello, K., Werneck, C., Silva, L., Valente, A.P., Mulloy, B., Highly sulfated dermatan sulfates from ascidians. Structure versus anticoagulant activity of these glycosaminoglycans (1998) J. Biol. Chem., 273 (43), pp. 27848-27857
• Tollefsen, D.M., Pestka, C.A., Monafo, W., Activation heparin cofactor II by dermatan sulfate (1983) J. Biol. Chem., 258 (11), pp. 6713-6716
• Griffith, M.J., Marbet, G.A., Dermatan Sulfate and Heparin can be fractionated by affinity for Heparin II Cofactor (1983) Biochem. Biophys. Res. Commun., (112), pp. 663-670
• Tollefsen, D.M., Peacock, M.E., Monafo, W.J., Molecular size of dermatan sulfate oligosaccharides required two bind an activate Heparin cofactor II (1986) J. Biol. Chem., (261), pp. 8854-8858
• Maimone, M., Tollefsen, D.M., Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity (1990) J. Biol. Chem., 265 (39), pp. 18263-18271
• Lindahl, U., (1989) Heparin: Chemical and Biological Properties, Clinical Applications, pp. 159-189. , D.A. Lane, & U. Lindahl. London: Edward Arnold
• Lam, L.H., Silbert, J.E., Rosenberg, R.D., The separation of active and inactive formas of heparin (1976) Biochem. Biophys. Res. Comm., 69 (2), pp. 570-577
• Griffith, M.J., Heparin-catalyzed inhibitor/proteases reactions: Kinetic evidence for common mechanism of action of heparin (1983) Proc. Natl. Acad. Sci. U. S. A., 80, pp. 5460-5464
• Ofosu, F.A., Modi, G.J., Blajchman, M.A., Buchanan, M.R., Johnson, E.A., Increased sulphation improves the anticoagulant activities of heparan sulphate and dermatan sulphate (1987) Biochem. J., 248, pp. 889-896
• Scully, M.F., Seno, E.N., Kakkar, V.V., Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II (1988) Biochem. J., 254, pp. 547-551
• Andoniades, S.E., Schenone, M., Recondo, E.F., Fernández De Recondo M E, Y., Influencia del grado de sulfatación en la actividad biológica del dermatan sulfato y del condroitin sulfato C (2002) J. Arg. Chem. Soc., 90 (1-3), pp. 21-26

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------